Natixis Advisors LLC Has $6.25 Million Holdings in Takeda Pharmaceutical Co. (NYSE:TAK)

Key Points

• Natixis Advisors LLC reduced its stake in Takeda Pharmaceutical Co. by 12.2%, selling 58,301 shares and leaving them with a total of 420,278 shares valued at approximately $6.25 million.
• Despite Natixis's sale, other institutional investors increased their holdings, with GAMMA Investing LLC raising their stake by 22.6% and Russell Investments Group Ltd. increasing theirs by 48.6%.
• Takeda Pharmaceutical's shares were trading at $14.30, having a market cap of $45.49 billion, and reported an earnings per share (EPS) of $0.52 for the last quarter.

Natixis Advisors LLC lowered its position in Takeda Pharmaceutical Co. (NYSE:TAK - Free Report) by 12.2% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 420,278 shares of the company's stock after selling 58,301 shares during the quarter. Natixis Advisors LLC's holdings in Takeda Pharmaceutical were worth $6,250,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in TAK. Vise Technologies Inc. lifted its position in shares of Takeda Pharmaceutical by 3.1% during the 4th quarter. Vise Technologies Inc. now owns 34,635 shares of the company's stock valued at $459,000 after acquiring an additional 1,026 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Takeda Pharmaceutical by 29.2% in the 1st quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company's stock worth $69,000 after purchasing an additional 1,045 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in Takeda Pharmaceutical by 5.4% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company's stock worth $319,000 after purchasing an additional 1,098 shares during the period. Allworth Financial LP boosted its stake in Takeda Pharmaceutical by 12.7% in the 1st quarter. Allworth Financial LP now owns 10,797 shares of the company's stock worth $163,000 after purchasing an additional 1,215 shares during the period. Finally, Choreo LLC boosted its stake in Takeda Pharmaceutical by 6.1% in the 1st quarter. Choreo LLC now owns 21,262 shares of the company's stock worth $316,000 after purchasing an additional 1,229 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Takeda Pharmaceutical Trading Up 0.7%

Takeda Pharmaceutical stock traded up $0.10 during midday trading on Friday, reaching $14.46. The stock had a trading volume of 3,045,379 shares, compared to its average volume of 5,686,498. The firm's fifty day simple moving average is $14.82 and its two-hundred day simple moving average is $14.55. Takeda Pharmaceutical Co. has a twelve month low of $12.80 and a twelve month high of $15.53. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The firm has a market cap of $46.01 billion, a price-to-earnings ratio of 48.20 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last posted its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 EPS for the quarter, topping analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a net margin of 3.20% and a return on equity of 10.50%. The firm had revenue of $7.45 billion during the quarter, compared to analyst estimates of $7.96 billion. Equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 EPS for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.